Business Wire

Proteintech Germany triples its space with a new office and laboratory

20.3.2024 21:57:00 EET | Business Wire | Press release

Share

Proteintech, the benchmark in antibodies and life science solutions, announces that its branch in Martinsried near Munich has moved into its new laboratory and office space. The new building houses research and development, production, logistics and administration in an area more than three times larger than its previous space.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320643097/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Proteintech celebrates the opening with a ribbon cutting event. Pictured: Dr. Jason Li, CEO of Proteintech, along with Proteintech executives and local government officials. (Photo: Business Wire)

In 2020, the Proteintech Group acquired ChromoTek GmbH, which specializes in the development and production of Nanobody-based reagents and was located at the incubator IZB. The gradual integration of Chromotek into the parent company, Proteintech Group, enabled new sales markets and channels for the products manufactured in Martinsried. The Martinsried site also serves as a central logistics hub for all Proteintech products for customers in the European Union.

Rainer Gebhart, Site Manager at Proteintech Germany, said: “Here we offer state-of-the-art working environments for daily top performance and innovation of our employees - our most important capital for a continued successful future.” He also explained, “The move supports our customer focused strategy. With a larger team in Martinsried – and in cooperation with our sister site in Manchester, UK – we can better serve our customers in Europe and further gain market share.”

Dr Jason Li, CEO of Proteintech said, “There is a great future for Nanobody technology and we’re excited to be at the forefront of this.” He also stated, “Proteintech has R&D and production laboratories on three continents in its major sites (Chicago, Wuhan and Martinsried). All three sites have seen expansion in the past year and the collaboration between them means we can bring new and innovative products to the market.”

About Proteintech Group

Proteintech Group Inc., founded in 2001, is a leading manufacturer of antibodies, proteins, nanobodies, and immunoassays. Proteintech has the largest proprietary portfolio of self-manufactured antibodies covering 2/3 of the human proteome. Proteintech offers antibodies, proteins and immunoassays across research areas with over 200,000 products cited. In addition, Proteintech produces cytokines, growth factors and other proteins that are human expressed, bioactive and cGMP-grade. Proteintech sites are ISO13485 and ISO9001 accredited.

To learn more about Proteintech, please visit www.ptglab.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Katie Bellows
katie@ptglab.com
ph. +1-312-455-8498

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

JERA Signs a Binding Heads of Agreement with AM Green for Long-Term Supply of Green Ammonia for Maritime Decarbonization27.10.2026 14:11:00 EET | Press release

JERA Co., Inc. (JERA) and AM Green Ammonia (India) Private Limited (AM Green) today jointly announced that it has entered into a Binding Heads of Agreement ("HoA") with AM Green regarding the long-term supply of green ammonia produced in India. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027189014/en/ JERA and AM Green have agreed upon supply of approximately 70,000 tonnes of green ammonia annually over five years, with potential extension of term for additional supply. The green ammonia is intended to be supplied through receiving, storage and distribution facilities being developed adjacent to JERA's Hekinan Thermal Power Station in Aichi Prefecture, Japan. Green ammonia would primarily be supplied to a business venture jointly to be established by Kawasaki Kisen Kaisha, Ltd. and Nippon Yusen Kabushiki Kaisha, which plans to utilize an ammonia bunkering vessel to supply fuel to ammonia-fueled car carriers. This marks

Avis First Expands to London Heathrow and Paris Charles de Gaulle Airports27.10.2026 14:01:00 EET | Press release

Avis announced the expansion of Avis First to London Heathrow and Paris Charles de Gaulle airports, bringing its premium car rental service to more than 30 airport and city locations across North America and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027269041/en/ Avis announced the expansion of Avis First to London Heathrow and Paris Charles de Gaulle airports, bringing its premium car rental service to more than 30 airport and city locations across North America and Europe. Available exclusively through the Avis mobile app, Avis First makes traveling easier and more efficient from the beginning to the end of every trip with coordinated vehicle delivery and return and concierge support throughout the rental. The frictionless experience has resonated with customers as evidenced by high repeat booking rates and strong customer satisfaction ratings. “First class shouldn’t end at the gate,” said Brian Choi, Chief

Pythia Labs Launches with AI-Designed Antibodies for Hard-to-Drug Targets27.10.2026 14:00:00 EET | Press release

Pythia Labs, a biotechnology company building frontier AI models for therapeutic discovery, today announced its launch alongside a preprint in bioRxiv introducing Pythia-1, the all-atom generative model at the core of its antibody design platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027891477/en/ Pythia's AI technology platform can design antibodies against traditionally challenging targets such as multi-pass membrane proteins. Pythia’s technology is built to create antibodies against targets that have challenged conventional discovery, including multi-pass membrane proteins such as G protein-coupled receptors (GPCRs). Generating antibodies that activate these receptors has been a longstanding goal in antibody discovery. Pythia-1 reasons jointly over amino acid sequence, three-dimensional atomic structure and explicit design specifications. The platform provides control over where an antibody binds, the conform

Robbyant’s Inaugural Embodied AI Challenge Draws Over 1,800 Teams Ahead of Real-Robot Final in Shanghai27.10.2026 13:00:00 EET | Press release

Qualifier submissions for the inaugural Robbyant Embodied AI Challenge officially closed on October 27, marking the end of the competition’s online preliminary round. Organized by Robbyant, an embodied AI company within Ant Group, the challenge was launched in September at the 2026 Inclusion Conference on the Bund in partnership with ModelScope and Alibaba Cloud Tianchi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027768483/en/ The competition is based on the open-source LingBot-VLA 2.0 embodied foundation model and is designed for developers working on embodied AI algorithms. Participants are evaluated on model training and fine-tuning, simulation-based generalization, and adaptation to real robots. The challenge is open to enterprises, universities, individual developers and technology enthusiasts worldwide. More than 1,800 teams and thousands of developers from 13 countries have registered for the challenge. Partici

Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 202627.10.2026 12:30:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the third quarter ended September 30, 2026, and provide an update on recent developments, on November 3, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on November 3, 2026. A live webcast of the call will be available at the following link: https://lifescievents.com/event/csy40je/. The webcast will be archived for 30 days. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye